
Extended collaboration targeting cell therapies generates revenues of EUR 130,000 in 2023

In November 2022, AcouSort reported that the company had entered a collaboration with a global life science company active within the cell therapy field. The first part of the project is now successfully finalized, and the two companies have jointly decided to extend the collaboration with a second phase generating revenues of EUR 130 000 to AcouSort in 2023. Cell therapy is an area where AcouSort sees great potential for the company's technology within sample preparation automation.

The continued collaboration aims to further explore how AcouSort's AcouWash technology can be adapted for the partner's specific application including integration of design suggestions to enable the development of OEM components in the partnering company's future cell therapy products and instruments. The second phase of the collaboration project generates revenues of EUR 130,000 to AcouSort in 2023. The continued collaboration verifies the commercial potential of AcouSort's focus on developing technology towards OEM separation modules to be used for cell therapy solutions in clinical settings.

"We are most happy to see the continuation of this exciting project where we will have the opportunity to further develop our technology to meet the needs of the cell therapy market. The continued collaboration enables us to direct our efforts and accelerate the development towards dedicated cell therapy OEM modules", says AcouSort's CEO Torsten Freltoft.

This information is information that AcouSort AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted, through the agency of the contact person below, for publication on January 20, 2023, at 11:30 am.

For further information on AcouSort, please contact:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Erik Penser Bank, 08-463 83 00, mail to: certifiedadviser@penser.se Erik Penser Bank AB (publ), Apelbergsgatan 27, Box 7405, 103 91 Stockholm.